Clinical trials: MDS-EB-1
Cancer, MDS-EB
A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML
INMB-INB16-002 is a Phase I open-label, dose escalation study of INKmune therapy in subjects with myelodysplastic syndrome (MDS) with excess blasts without Auer rods (EB-1 or 2, or CMML 1 or 2) or subjects with acute myeloid…
- Conditions
- Cancer, MDS-EB, Myelodysplastic Syndromes, Acute Myeloid Leukemia
- Trial name
- LAUREL (NCT05933070)
- Testing
- INKmune
- Where
- 3 sites in Greece, United Kingdom
- Volunteers
- 2 people
- Sponsor
- Inmune Bio, Inc.
Leukemia (Both ALL and AML), MDS-EB-1
Ikervis for DED Due to GVHD Post Allo-HSCT
Dry eye disease (DED) is a common sequelae of graft versus host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
- Trial name
- Ikervis (NCT04636918)
- Testing
- Cyclosporine Ophthalmic
- Where
- Singapore
- Volunteers
- 40 people
- Sponsor
- Singapore Eye Research Institute